Seeger Weiss Earns Expanded Recognition in Chambers USA 2026

Seeger Weiss is proud to announce that the firm, alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya, has been recognized in the newly released Chambers 2026 USA Guide.

June 8, 2026

2026 Chambers USA Guide SW

Seeger Weiss is proud to announce that the firm, alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya, has been recognized in the newly released Chambers 2026 USA Guide.

Seeger Weiss retained its Band 1 standing in Litigation: Mainly Plaintiffs in New Jersey and its Band 1 ranking in Product Liability: Plaintiffs in the USA, reaffirming Seeger Weiss’s position among the country’s leading plaintiff-side litigation firms. The firm also earned a Band 2 ranking in E-Discovery & Information Governance: Plaintiffs in the USA, a new category for the firm this year.

Partners Christopher Seeger and David Buchanan each earned Band 1 recognition in both Litigation: Mainly Plaintiffs in New Jersey and Product Liability: Plaintiffs in the USA continuing their long-standing presence at the top of the Chambers rankings.

Partner Ben Barnett earned three Chambers distinctions this year. He received a new Band 1 ranking in E-Discovery & Information Governance: Plaintiffs in the USA and was selected for inclusion in Band 3 for E-Discovery & Information Governance in the USA, continuing his years-long streak in that category. He was also recognized in Band 3 in the 2026 E-Discovery & Information Governance Global Guide.

Partner Parvin Aminolroaya was recognized in Band 1 for Litigation: Mainly Plaintiffs in New Jersey, building on her first Chambers recognition in 2025.

For over three decades, Chambers has been a trusted authority in legal research and insights, with inclusion in their guides widely recognized as an honor in the legal profession.

Seeger Weiss has built its reputation handling some of the most complex mass tort and class action litigation in the country, representing individuals, companies, and governments in both state and federal court. The firm’s consistent recognition across multiple Chambers categories reflects the depth and breadth of its practice.

Chambers identifies the best practice groups and lawyers in 200 jurisdictions across the globe. The guide’s selection process is performed through in-depth market analysis and independent research conducted by a dedicated team of Research Analysts who speak to law firm clients/referees to analyze the level of client services and work each submitting law firm offers.

The selection methodology can be found here.

No aspect of this advertisement has been approved by the Supreme Court of New Jersey.

Related News

October 30, 2026
Seeger Weiss Named Litigation Department of the Year for Products Liability and Mass Torts at the 2026 New Jersey Legal Awards

New Jersey-based Seeger Weiss has been named Litigation Department of the Year in the Products Liability and Mass Torts category at the New Jersey Law Journal’s 2026 New Jersey Legal Awards. Winners were announced on October 29, 2026, at The Palace at Somerset Park in Somerset, New Jersey. Over the past year, the department took […]

Read More
October 25, 2026
Seeger Weiss Partner Christopher A. Seeger Receives Inaugural Monroe E. Price Award from the Benjamin N. Cardozo School of Law

Seeger Weiss Partner Christopher Seeger received the inaugural Monroe E. Price Award from the Benjamin N. Cardozo School of Law, his alma mater, at the school’s 50th Anniversary Gala at the Hall des Lumières in New York City on October 22, 2026. The award is named for Monroe Price, who served as Dean of Cardozo […]

Read More
October 23, 2026
Seeger Weiss’s Christopher A. Seeger Appointed Co-Lead Counsel in In re: Dupixent (Dupilumab) Products Liability Litigation

Seeger Weiss LLP is pleased to announce that Partner Christopher A. Seeger has been appointed Co-Lead Counsel in In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, pending in the U.S. District Court for the District of New Jersey. The litigation involves claims that Dupixent, an injectable biologic prescribed to treat inflammatory conditions including […]

Read More
↑